Cargando…

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

PURPOSE: Vorinostat has been shown to overcome resistance to gefitinib. We performed a phase I/II study combining gefitinib with vorinostat in previously treated non-small cell lung cancer (NSCLC). METHODS: A 3 + 3 dose-escalation design was used to determine maximum tolerated dose (MTD) and recomme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ji-Youn, Lee, Soo Hyun, Lee, Geon Kook, Yun, Tak, Lee, Young Joo, Hwang, Kum Hui, Kim, Jin Young, Kim, Heung Tae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341018/ https://www.ncbi.nlm.nih.gov/pubmed/25552401 http://dx.doi.org/10.1007/s00280-014-2664-9

Ejemplares similares

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib
por: Kim, Hyojeong, et al.
Publicado: (2013)

Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
por: Giannelli, G, et al.
Publicado: (2004)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
por: Knight, Louise A, et al.
Publicado: (2004)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
por: Stahel, R, et al.
Publicado: (2003)

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
por: Camirand, Anne, et al.
Publicado: (2005)

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2021)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Alitretinoin Treatment for Gefitinib-Induced Paronychia
por: Lee, Soo Young, et al.
Publicado: (2019)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
por: Lee, Youngjoo, et al.
Publicado: (2017)

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma
por: Yun, Tak, et al.
Publicado: (2011)

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Young Saing, et al.
Publicado: (2016)

Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
por: Kwak, Tae Won, et al.
Publicado: (2015)

Artificial Ivory
Publicado: (1883)

The Ivory Plant
Publicado: (1889)

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer
por: Kim, Joohae, et al.
Publicado: (2019)

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
por: Jeannot, Victor, et al.
Publicado: (2016)

An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
por: Kwon, Taeho, et al.
Publicado: (2015)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Dissecting the Illegal Ivory Trade: An Analysis of Ivory Seizures Data
por: Underwood, Fiona M., et al.
Publicado: (2013)

Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro
por: Lee, Eunju, et al.
Publicado: (2015)

Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells
por: Lee, Sook-Jeong, et al.
Publicado: (2014)

Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells
por: Kwak, Tae Won, et al.
Publicado: (2017)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

Ivory Coast : the challenge of success : report of a mission sent to the Ivory Coast by the World Bank /
Publicado: (1978)

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
por: Yun, Tak, et al.
Publicado: (2016)

Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells
por: Kwak, Tae Won, et al.
Publicado: (2013)

Ivory anatomical manikins.
por: Russell, K F
Publicado: (1972)

To Render Ivory Flexible
Publicado: (1881)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q8ghpjql6q3m7v633prolqnmgh